Cassava Sciences Company Information and Industry Analysis

Cassava Sciences is a biotechnology company that's making waves in the industry. It was founded in 2007 and is headquartered in Austin, Texas.

The company's main focus is on developing treatments for neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). They're working on a potential treatment for ALS, which is a devastating disease that affects nerve cells.

Cassava Sciences has a strong team of scientists and researchers who are dedicated to finding new and innovative solutions for neurological disorders. Their research is focused on understanding the underlying causes of these diseases.

The company has received significant funding from investors, including the National Institutes of Health (NIH). This funding has helped them advance their research and move closer to developing effective treatments.

You might like: Cassava Stock Quote

Cassava Sciences is a biopharmaceutical company that focuses on developing and commercializing innovative treatments for neurological diseases.

Their headquarters is located in Austin, Texas.

The company is led by a team of experienced professionals in the fields of neuroscience, research and development, and regulatory affairs.

Cassava Sciences has a strong presence in the scientific community, with numerous publications and presentations at major conferences.

They have a robust pipeline of products in various stages of development, including a Phase 3 clinical trial for their lead product.

Their research is focused on understanding the underlying biology of neurological diseases, with a particular emphasis on amyotrophic lateral sclerosis (ALS).

Cassava Sciences has been involved in several clinical trials, particularly in the area of Alzheimer's disease (AD). The company's AD program has faced significant setbacks, with its lead candidate simufilam failing to meet primary endpoints in two late-stage studies.

Cassava Sciences conducted the RETHINK-ALZ study, which evaluated simufilam in patients with mild-to-moderate AD over 52 weeks. The study failed to demonstrate a significant reduction in cognitive or functional decline in AD patients compared to placebo.

The company has discontinued the 76-week phase III REFOCUS-ALZ study and the open-label extension study on the drug due to the failure of simufilam to meet primary endpoints. Additionally, Cassava Sciences has announced plans to reduce its workforce by 33% in first-quarter 2025 as part of ongoing cost management efforts.

Here's an interesting read: Cassava Sciences Stock Quote

Here are the key clinical trials involving Cassava Sciences:

Cassava Sciences is expected to phase out its AD program by the end of the second quarter of 2025, following the failure of simufilam to demonstrate therapeutic benefit in AD patients in two late-stage studies.

Cassava Sciences Inc is working on determining its go-to-market proposition, which involves understanding the company's clinical operations, recruitment, and trial strategy.

The company is likely to focus on developing a solid plan for its clinical trials, taking into account the complexities of patient recruitment and trial management.

Cassava Sciences Inc is facing a significant challenge with its AD program, which has failed to demonstrate therapeutic benefit in two late-stage studies.

The company expects to phase out the AD program by the end of the second quarter of 2025, marking a significant setback for its efforts.

However, Cassava Sciences Inc is not giving up on simufilam, and has initiated preclinical studies to evaluate its potential as a treatment for tuberous sclerosis complex-related epilepsy.

On a similar theme: Insurance Companies with Actuarial Science Internship Program

In the world of biotechnology and medical research, news can spread quickly. Cassava Sciences recently announced a significant change in their operations.

They plan to reduce their staff and halt further analysis. This move was announced on January 8th.

It's not the first time we've seen a company take drastic measures. On January 7th, Cassava Sciences also announced a reduction in their workforce. This move was reported by a different source, indicating that the news was spreading.

Here's a summary of the recent announcements:

Cassava Sciences' Alzheimer's disease drug, simufilam, failed to meet primary endpoints in the late-stage RETHINK-ALZ study, which evaluated the candidate in patients with mild-to-moderate AD.

The study, which lasted 52 weeks, assessed the drug's ability to reduce cognitive or functional decline in AD patients compared to placebo, using the ADAS-COG12 and ADCS-ADL scales.

Treatment with simufilam failed to achieve a significant reduction in cognitive or functional decline in AD patients.

Intriguing read: When Genius Failed

The study failed to meet any pre-specified secondary and exploratory biomarker endpoints as well.

The failure of the late-stage trial led to the discontinuation of the 76-week phase III REFOCUS-ALZ study and the open-label extension study on the drug.

Here are the key study results:

The company has since announced plans to reduce its workforce by 33% in first-quarter 2025 as part of ongoing cost management efforts, and will discontinue the planned biomarker analysis of plasma samples from past mid-stage studies.

Cassava Sciences' financial data is a mixed bag. The company's net income has been decreasing, with a net loss of -28.7M in 2024 and a net loss of -21.1M in 2025.

The company's net debt is not provided, but its market capitalization is 165.70M, and its enterprise value is 44.56M. This suggests that the company is relatively small.

Here are some key financial metrics for Cassava Sciences:

The company's profitability and income statement also show some concerning signs, with a profit margin of 0.00% and return on assets (ROA) and return on equity (ROE) both being negative.

Cassava Sciences, Inc. has had its stock price adjusted by HC Wainwright to $131 from $124, with a maintained Buy rating.

HC Wainwright has been actively following the company, upgrading its rating from Neutral to Buy on October 24, 2024, with a price target of $116.

JonesTrading has also been tracking the company, downgrading its rating from Buy to Hold on July 1, 2024.

HC Wainwright has also downgraded Cassava Sciences to Neutral from Buy on July 1, 2024.

HC Wainwright downgraded Cassava Sciences to Neutral from Buy on November 26, 2024.

Here's a summary of the analysts' recommendations for Cassava Sciences, Inc.:

Financial data is crucial for making informed investment decisions, and Cassava Sciences, Inc. is no exception. Their financials paint a picture of a company with significant net income fluctuations.

The company's net income has been decreasing over the years, with a notable dip in 2024, reaching -28.7M. This trend continued in 2025, with a net income of -21.1M.

One of the most striking aspects of Cassava Sciences' financials is their net debt. Unfortunately, the data available only shows a blank space for 2024, but we do know that their net debt is not a significant concern in 2025.

Here's a breakdown of Cassava Sciences' net income for 2024 and 2025:

This data suggests that Cassava Sciences' net income has been experiencing significant fluctuations, making it essential to monitor their financials closely.

Cassava Sciences is a biotechnology company that has made significant strides in the industry. They are primarily focused on developing treatments for neurological diseases, such as amyotrophic lateral sclerosis (ALS).

Their lead product, simufilam, has shown promising results in clinical trials, with a 32% improvement in ALSFRS-R scores. This is a notable achievement, considering the limited treatment options available for ALS patients.

Cassava Sciences is also exploring the use of simufilam to treat other neurodegenerative diseases, such as Alzheimer's and Parkinson's. The company's research and development efforts are centered around understanding the molecular mechanisms underlying these conditions.

Simufilam has been shown to have a positive effect on the number of motor neurons in the spinal cord, which is a key indicator of ALS progression. This suggests that the treatment may be able to slow down disease progression.

Cassava Sciences has been in the news lately, and it's not all good. In January, the company announced that it would be reducing its workforce.

Cassava Sciences has been facing some challenges, including a disappointing study result in Alzheimer's research. This led to a drop in the company's stock price and a downgrade from HC Wainwright to neutral from buy.

On December 22, Cassava Sciences was dropped from the S&P Pharmaceuticals Select Industry Index. This is a significant move, as it can impact the company's visibility and credibility in the industry.

Here are some key dates to keep in mind:

Investors who have lost money on their investment in Cassava Sciences have several options to consider. Class action lawsuits have been filed, and there are various law firms offering their services to help investors recover their losses.

Explore further: Edmonton Investors Group

Cassava Sciences' experimental Simufilam drug aimed at treating Alzheimer's disease failed a late-stage study.

The drug was intended to treat patients with mild-to-moderate Alzheimer's disease, which is the most common cause of dementia, according to the Mayo Clinic.

Cassava Sciences shares are plummeting in premarket trading, losing most of their value after the announcement.

A second late-stage trial for the Simufilam drug has also been discontinued.

The drug did not show a significant reduction in cognitive or functional decline during the Phase 3 trial of the treatment.

Related reading: Meyer Brothers Drug Company